The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pasireotide Treatment for Neuroendocrine Tumor
Official Title: Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
Study ID: NCT02779257
Brief Summary: Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Name: Kashif M Munir, MD
Affiliation: University of Maryland, Baltimore
Role: PRINCIPAL_INVESTIGATOR